TAIPEI and SAN DIEGO, Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the appointment of Dr. Yiu-Lian Fong to the board of directors...
Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director
Seaking AlphaSeeking Alpha / Seaking Alpha 3 hours ago 1 Views
Comments